varieti
good
manufactur
practic
gmp
compliant
process
report
product
nonrepl
adenoviru
vector
import
challeng
remain
clinic
develop
adenoviru
vector
use
simian
adenovirus
rare
human
serotyp
wherea
report
manufactur
process
mainli
use
serotyp
question
relev
clinic
vaccin
develop
mani
clinic
relev
vaccin
transgen
interfer
adenoviru
replic
wherea
report
process
develop
use
select
antigen
even
model
transgen
fluoresc
protein
caus
littl
interfer
process
typic
develop
singl
adenoviru
serotyp
transgen
combin
requir
extens
optim
new
vaccin
need
rapid
product
platform
small
gmp
batch
nonrepl
adenoviru
vector
earlyphas
vaccin
trial
particularli
prepar
respons
emerg
pathogen
outbreak
platform
must
robust
variat
transgen
ideal
also
capabl
produc
adenovirus
one
serotyp
also
highli
desir
process
readili
implement
new
facil
use
commerci
avail
singleus
materi
avoid
need
develop
bespok
tool
clean
valid
readili
scalabl
laterstag
studi
report
develop
process
use
singleus
stirredtank
bioreactor
transgenerepress
cell
promot
combin
fulli
singleus
filtrat
ion
exchang
compon
demonstr
applic
process
candid
vaccin
rabi
malaria
rift
valley
fever
base
differ
adenoviru
serotyp
compar
perform
rang
commerci
avail
ion
exchang
media
includ
believ
first
publish
use
novel
media
adenoviru
purif
natriflo
hdq
merck
demonstr
need
minim
process
individu
vaccin
product
fulfil
regulatori
qualiti
expect
cellspecif
yield
upper
end
previous
report
literatur
volumetr
yield
rang
purifi
viru
particl
per
litr
cultur
l
process
comfort
adequ
produc
vaccin
earlyphas
trial
process
readili
transfer
gmp
facil
capabl
mammalian
cell
cultur
asept
fill
steril
product
varieti
good
manufactur
practic
gmp
compliant
process
report
product
nonrepl
adenoviru
vector
import
challeng
remain
clinic
develop
adenoviru
vector
use
simian
adenovirus
rare
human
serotyp
wherea
report
manufactur
process
mainli
use
serotyp
question
relev
clinic
vaccin
develop
mani
clinic
relev
vaccin
transgen
interfer
adenoviru
replic
wherea
report
process
develop
use
select
antigen
even
model
transgen
fluoresc
protein
caus
littl
interfer
process
typic
develop
singl
adenoviru
serotyp
transgen
combin
requir
extens
optim
new
vaccin
need
rapid
product
platform
small
gmp
batch
nonrepl
adenoviru
vector
earlyphas
vaccin
trial
particularli
prepar
respons
emerg
pathogen
outbreak
platform
must
robust
variat
transgen
ideal
also
capabl
produc
adenovirus
one
serotyp
also
highli
desir
process
readili
implement
new
facil
use
commerci
avail
singleus
materi
avoid
need
develop
bespok
tool
clean
valid
readili
scalabl
laterstag
studi
report
develop
process
use
singleus
stirredtank
bioreactor
transgenerepress
cell
promot
combin
fulli
singleus
filtrat
ion
exchang
compon
demonstr
applic
process
candid
vaccin
rabi
malaria
rift
valley
fever
base
differ
adenoviru
serotyp
compar
perform
rang
commerci
avail
ion
exchang
media
includ
believ
first
publish
use
novel
media
adenoviru
purif
natriflo
hdq
merck
demonstr
need
minim
process
individu
vaccin
product
fulfil
regulatori
qualiti
expect
cellspecif
yield
upper
end
previous
report
literatur
volumetr
yield
rang
purifi
viru
particl
per
litr
cultur
l
process
comfort
adequ
produc
vaccin
earlyphas
trial
process
readili
transfer
gmp
facil
capabl
mammalian
cell
cultur
asept
fill
steril
product
histor
develop
novel
vaccin
painstak
process
take
mani
year
involv
develop
entir
bespok
manufactur
process
approach
incap
deliv
rapid
respons
emerg
pathogen
also
unsuit
develop
nich
vaccin
diseas
small
commerci
marketsfor
exampl
human
diseas
signific
problem
within
restrict
geograph
area
livestock
diseas
predominantli
affect
lowincom
countri
even
person
cancer
vaccin
contrast
platform
technolog
subunit
vaccin
allow
applic
singl
vaccin
product
method
induct
immun
respons
protein
antigen
interest
key
group
platform
viral
vector
vaccin
use
replicationdefici
viru
deliv
transgen
encod
antigen
interest
express
recipi
cell
principl
manufactur
vector
similar
regardless
encod
antigen
among
major
class
viral
vector
adenovirus
arguabl
versatil
potent
induc
combin
antibodi
cell
respons
virus
lack
region
replicationincompet
outsid
helper
cell
high
level
assur
gener
replicationcompet
viru
achiev
preexist
immun
human
adenovirus
human
popul
may
inhibit
effect
vaccin
vector
overcom
use
simian
adenovirus
shown
safe
excel
immunogen
variou
human
popul
includ
african
children
adult
without
patient
select
basi
preexist
antivector
immun
rare
human
serotyp
may
similar
properti
result
signific
invest
larg
pharmaceut
compani
develop
highyield
costeffect
largescal
adenoviru
product
process
adenovirusvector
vaccin
ebola
licens
china
numer
candid
clinic
trial
advanc
preclin
develop
target
diseas
includ
malaria
middl
east
respiratori
syndrom
respiratori
syncyti
viru
varieti
cancer
keep
potenti
also
fact
adenovirusbas
gene
therapi
intens
investig
extens
literatur
regard
gmpcompliant
adenoviru
product
process
suspens
cell
commonli
use
batchmod
stirredtank
upstream
process
although
highest
volumetr
yield
report
perfusionbas
process
cell
downstream
process
commonli
made
use
beadbas
anion
exchang
resin
often
addit
polish
step
size
exclus
hydrophob
interact
multimod
coreshel
eg
captocor
chromatographi
recent
membranebas
monolithbas
chromatographi
use
previou
public
describ
adenoviru
product
process
report
care
optim
manufactur
singl
vector
often
use
serotyp
andor
model
transgen
green
fluoresc
protein
lack
relev
clinic
vaccin
develop
mark
differ
growth
characterist
differ
virus
observ
vari
adenoviru
serotyp
pathogenderiv
transgen
use
necessit
optim
product
process
individu
viru
clearli
undesir
lowcost
manufactur
outbreak
respons
extrem
case
inhibit
viral
growth
transgen
toxic
result
failur
viral
rescu
genet
instabl
partli
result
variabl
product
initi
good
manufactur
practic
gmp
compliant
batch
viru
earlyphas
clinic
trial
remain
bottleneck
adenovirusvector
vaccin
develop
pipelin
clinic
biomanufactur
facil
cbf
among
experienc
facil
manufactur
batch
produc
gmp
adenoviru
numer
clinic
trial
past
decad
accomplish
use
simpl
method
involv
shakeflaskbas
upstream
process
ultracentrifugationbas
downstream
process
process
robust
labourintens
scalabl
requir
preced
period
productspecif
process
develop
limit
cleanroom
throughput
around
three
batch
per
year
set
develop
gmpsuitabl
process
suffici
robust
use
across
multipl
adenoviru
serotyp
carri
varieti
pathogen
transgen
minim
productspecif
process
develop
although
princip
focu
product
initi
gmp
batch
earlyphas
clinic
trial
aim
use
process
techniqu
suitabl
subsequ
scaleup
throughout
sought
make
process
simpl
possibl
use
entir
offtheshelf
materi
dispos
productcontact
part
aim
facilit
adopt
facil
littl
experi
adenoviru
product
avoid
doubt
throughout
manuscript
merck
refer
european
entiti
merck
kgaa
known
milliporesigma
north
america
deriv
rabg
metrap
vaccin
previous
describ
briefli
rabg
vector
express
rabi
viru
glycoprotein
base
upon
chimpanze
adenoviru
serotyp
modif
region
metrap
chimpanze
adenoviru
serotyp
vector
express
multiepitop
string
thrombospondin
relat
adhes
protein
plasmodium
falciparum
rvf
vaccin
use
similar
previous
report
except
modifi
codon
usag
gngc
transgen
sequenc
design
avoid
repetit
sequenc
vector
base
upon
chimpanze
adenoviru
serotyp
modif
region
express
rift
valley
fever
viru
glycoprotein
gn
gc
purifi
viru
inocula
use
infect
cultur
smallscal
gradientelut
ion
exchang
experi
standard
qualiti
control
assay
produc
caesium
chlorid
densitygradi
ultracentrifug
jenner
institut
viral
vector
core
facil
master
cell
bank
trex
cell
invitrogen
produc
gmp
condit
subject
test
compliant
pharmacopoei
requir
cell
adapt
suspens
growth
media
mm
lglutamin
thermofish
mgml
blasticidin
melford
laboratori
gradual
reduc
concentr
foetal
bovin
serum
nonbaffl
polycarbon
erlenmey
flask
corn
shake
incub
kuhner
co
rpm
mm
orbit
media
serum
henceforth
refer
complet
medium
smallscal
upstream
process
experi
viru
growth
kinet
fig
ml
cultur
specifi
densiti
inocul
specifi
multipl
infect
moi
erlenmey
flask
h
later
feed
volum
fresh
complet
medium
ad
mobiu
merck
bioblu
eppendorf
singleus
bioreactor
vessel
use
accord
manufactur
instruct
gx
bioreactor
control
unit
cbio
softwar
global
process
control
use
control
vessel
type
dissolv
oxygen
regul
setpoint
air
satur
addit
medic
air
via
microsparg
ph
regul
rang
addit
co
sodium
bicarbon
solut
thermofish
requir
vessel
seed
ml
mobiu
l
bioblu
cultur
cellsml
inocul
viru
moi
three
hour
later
volum
fresh
complet
medium
ad
case
bioblu
vessel
optic
ph
transduc
eppendorf
use
noninvas
ph
sens
onepoint
calibr
optic
ph
sensor
perform
take
sampl
three
hour
vessel
setup
allow
time
equilibr
sensor
addit
feed
lysi
initi
h
infect
addit
cultur
volum
buffer
contain
vv
polysorb
wv
sucros
mm
mgcl
mm
tri
ph
plu
benzonas
merck
final
incultur
concentr
unitsml
ph
control
bioreactor
deactiv
agit
heat
continu
two
hour
addit
lysi
buffer
clarif
initi
except
initi
smallscal
comparison
filter
varieti
cm
unit
use
fig
cm
millistak
hc
pro
depth
filter
media
filter
use
merck
flow
rate
lminm
use
earli
experi
fig
subsequ
acceler
lminm
without
detriment
turbid
reduct
viru
recoveri
prior
use
filter
equilibr
vv
polysorb
wv
sucros
mm
mgcl
mm
tri
ph
complet
filtrat
lysat
cm
filter
flush
ml
buffer
unless
otherwis
specifi
result
section
tangenti
flow
filtrat
tff
perform
use
pellicon
mini
cassett
biomax
polyethersulfon
membran
cscreen
merck
conjunct
spectrum
process
reservoir
spectrum
laboratori
masterflex
tube
coleparm
singleus
pressur
sensor
pendotech
concentr
diafiltr
clarifi
lysat
first
tff
step
feed
flow
rate
lminm
use
minim
transmembran
pressur
pinch
valv
restrict
diafiltr
buffer
feed
rate
manual
adjust
match
permeat
flow
rate
maintain
constant
mass
process
reservoir
convers
rate
permeat
flow
proport
feed
flow
exceed
third
pump
use
permeat
control
concentr
clarifi
lysat
diafilt
ion
exchang
load
buffer
compris
mm
nacl
mm
mgcl
vv
polysorb
wv
sucros
mm
bistri
ph
follow
ion
exchang
chromatographi
iex
eluat
buffer
exchang
diavolum
formul
buffer
mean
second
tff
step
step
perform
use
either
pe
flat
sheet
modul
pellicon
mini
one
case
smaller
pellicon
modul
use
kda
mwco
pe
midikro
hollow
fibr
unit
spectrum
laboratori
whichev
modul
use
feed
flow
rate
second
tff
step
lminm
retent
pinch
valv
use
target
permeat
flow
rate
lminm
match
rate
addit
fresh
buffer
system
transfer
pump
typic
achiev
transmembran
pressur
c
bar
permeat
control
use
second
tff
second
tff
product
steril
passag
success
mm
mm
filter
cm
membran
area
merck
smallscal
anion
exchang
guid
media
select
perform
use
akta
purifi
ge
scaledown
columnscapsul
ml
bed
volum
mustang
q
acrodisc
pall
ml
cimmultu
monolith
bia
separ
ml
bed
volum
natriflo
hdq
recon
mini
disc
merck
buffer
use
load
buffer
describ
buffer
b
nacl
mm
mgcl
vv
polysorb
wv
sucros
mm
trishcl
ph
case
natriflo
hdq
devic
viru
bistrisbas
load
buffer
dilut
phosphatebas
load
buffer
prepar
titrat
mm
orthophosphor
acid
ph
sodium
hydroxid
dynam
bind
capac
dbc
assess
load
excess
prepurifi
rabg
sampl
load
buffer
lower
end
manufactur
recommend
flow
rate
rang
ion
exchang
medium
breakthrough
observ
assess
dbc
defin
load
breakthrough
exceed
observ
earli
load
ie
flowthrough
differ
load
sampl
flowthrough
wash
media
bed
volum
load
buffer
linear
gradient
increas
proport
buffer
b
load
buffer
appli
subsequ
elut
characterist
metrap
rvf
investig
similar
linear
gradient
elut
experi
use
mustang
q
acrodisc
capsul
assess
perform
media
step
elut
condit
diafilt
lysat
contain
rabg
load
manufactur
recommend
flow
rate
load
viru
particl
vp
mustang
q
natriflo
hdq
capsul
vp
largervolum
cimqa
column
wash
elut
buffer
prepar
mix
load
buffer
buffer
b
desir
conduct
obtain
buffer
conduct
select
basi
conduct
valu
centr
viru
elut
peak
linear
gradient
experi
wash
buffer
conduct
mscm
lower
valu
elut
buffer
conduct
mscm
higher
complet
load
load
buffer
wash
buffer
elut
buffer
buffer
b
appli
sequenc
bed
volum
ml
whichev
greater
buffer
appli
elut
viru
collect
applic
elut
buffer
analys
quantit
pcr
qpcr
vp
quantif
elisa
residu
host
cell
protein
see
atscal
chromatographi
mustang
q
capsul
ml
bed
volum
pall
use
peristalt
pumpdriven
rig
compris
masterflex
tube
cole
parmer
singleus
uv
absorb
conduct
pressur
sensor
pendotech
use
unless
otherwis
state
resultsfigur
legend
capsul
preequilibr
load
buffer
diafilt
lysat
load
flow
rate
mlmin
follow
wash
column
volum
load
buffer
wash
elut
condit
describ
smallscal
experi
wash
conduct
ident
elut
conduct
higher
mscm
due
lower
conduct
vaccin
elut
load
buffer
use
wash
elut
buffer
conduct
adjust
mscm
purifi
genomecontain
viru
particl
quantifi
uv
spectrophotometri
previous
describ
result
base
upon
mean
triplic
absorb
measur
infecti
unit
quantifi
cellbas
infect
assay
also
describ
previous
inprocess
sampl
genomecontain
viru
particl
quantifi
taqman
quantit
pcr
qpcr
use
probe
set
design
bind
noncod
region
adenovir
genom
common
forward
revers
primer
gtgggaaaagtgacgtcaaacgag
tgcatccgcc
tagaaacacctca
respect
probe
sequenc
gagagcgcgggaaaattgagtatt
label
tamrafam
thermofish
sampl
pretreat
benzonas
remov
unencapsid
viral
dna
follow
proteinas
k
treatment
releas
encapsid
genom
quantif
perform
rel
standard
curv
purifi
spectrophotometricallyquantifi
rabg
viru
sdspage
perform
use
bistri
gel
mop
run
buffer
nupag
sampl
buffer
supplement
dtt
thermofish
stain
quick
coomassi
generon
imag
use
chemidoc
system
biorad
quantif
empti
viral
capsid
purifi
viru
subject
isopycn
ultracentrifug
gml
cscl
h
g
rel
protein
content
upper
empti
capsid
lower
genomecontain
viru
particl
band
quantifi
run
sdspage
gel
follow
stain
use
silver
express
thermofish
densitometri
previous
report
residu
hostcel
protein
hcp
quantifi
use
hcp
elisa
kit
cygnu
technolog
accord
manufactur
instruct
case
inhous
version
assay
use
employ
standard
goat
hcp
antibodi
cygnu
technolog
antibodi
use
unconjug
horseradishperoxidasec
onjug
format
produc
use
lynx
rapid
kit
biorad
captur
detect
antibodi
respect
residu
benzonas
quantifi
use
benzonas
elisa
kit
ii
merck
accord
manufactur
instruct
residu
host
cell
dna
quantifi
use
previous
report
quantit
pcr
method
target
base
pair
amplicon
within
alu
repeat
compris
human
genom
copi
number
milliongenom
lower
limit
standard
curv
pgml
intact
dna
major
caus
need
productspecif
optimis
adenoviru
vector
product
process
fact
transgen
mark
impact
upon
growth
adenoviru
vector
other
previous
report
virus
carri
toxic
transgen
rescu
incorpor
tet
oper
element
transgen
promot
grow
viru
cell
trex
thermofish
procel
repress
express
modifi
promot
unfortun
howev
cell
line
wide
access
gmp
manufactur
suspens
cultur
adenoviru
manufactur
facil
thu
continu
use
nontetrepress
cell
gmp
manufactur
requir
empir
determin
optim
time
harvest
toh
multipl
infect
moi
individu
virus
prior
manufactur
produc
test
trex
cell
bank
suitabl
gmp
use
sought
investig
growth
vector
three
simian
serotyp
cell
deriv
serotyp
deriv
select
vector
encod
varieti
transgen
rvf
encod
gngc
antigen
rift
valley
fever
viru
rvf
rabg
encod
rabi
viru
glycoprotein
metrap
encod
previous
describ
malaria
antigen
examin
viru
yield
time
trex
cell
smallscal
shake
flask
maximum
cultur
volum
ml
compar
moi
cell
densiti
cellsml
time
infect
reduc
cellsml
addit
volum
feed
h
infect
aim
determin
strictli
optim
condit
would
requir
wider
rang
moi
cell
densiti
instead
assess
whether
could
identifi
standard
condit
provid
accept
yield
previou
work
suggest
cellspecif
product
reduc
cell
densiti
test
unless
complex
mediumexchang
perfus
method
use
given
aim
develop
simpl
transfer
method
restrict
lower
cell
densiti
simpli
sought
establish
readilyachiev
window
densiti
achiev
accept
yield
virus
yield
exceed
viru
particl
infecti
unit
per
ml
cultur
achiev
h
postinfect
either
cell
densiti
fig
superinfect
cell
moi
achiev
littl
addit
yield
versu
moi
fact
reduc
amplif
factor
output
yield
per
input
iu
yield
similar
cell
densiti
cellsml
infect
data
shown
h
major
viru
remain
cell
associ
h
much
viru
supernat
therefor
proceed
use
similar
condit
subsequ
work
toh
h
moi
cell
densiti
cellsml
point
infect
import
note
although
repress
transgen
express
substanti
reduc
variabl
virus
singl
serotyp
encod
differ
antigen
affect
fundament
growth
characterist
differ
serotyp
notabl
infect
consist
caus
rapid
cell
lysi
effect
seen
also
repeatedli
preclin
work
jenner
institut
viral
vector
core
facil
unpublish
observ
nonetheless
h
kinet
suffici
similar
allow
use
singl
toh
next
sought
implement
straightforward
procedur
cell
lysi
host
cell
dna
reduct
clarif
start
cultur
infect
rabg
paramet
observ
rapid
reduct
intact
host
cell
dna
level
assess
qpcr
lysi
detergentbas
buffer
presenc
unitsml
benzonas
incub
stir
fig
compar
rang
depth
filter
seek
identifi
candid
might
suitabl
singlestep
clarif
process
cm
scale
fulli
synthet
millistak
hc
pro
filter
milliporesigma
found
achiev
turbid
reduct
nephelometr
turbid
unit
ntu
evid
turbid
breakthrough
lm
backpressur
psi
fig
littl
differ
filter
effici
product
recoveri
data
shown
subsequ
experi
millistak
hc
pro
filter
demonstr
recoveri
consist
median
rang
n
base
upon
infect
unit
titrat
addit
flush
nacl
recov
minim
extra
viru
load
select
upstream
process
paramet
smallscal
shake
flask
experi
proceed
transfer
process
singleus
stir
tank
bioreactor
initi
work
rabg
explor
two
singleus
bioreactor
system
obtain
satisfactori
result
cultur
mobiu
milliporesigma
maximum
work
volum
occasion
use
two
vessel
parallel
total
cultur
volum
cultur
bioblu
eppendorf
maximum
work
volum
subsequ
work
rvf
metrap
perform
use
mobiu
vessel
typic
process
paramet
log
data
shown
fig
clarif
use
cm
millistak
hc
pro
depth
filter
media
filter
result
postclarif
turbid
ntu
run
virus
maxim
throughput
lm
turbid
breakthrough
observ
yield
shown
volumetr
basi
tabl
upstream
process
yield
per
bioreactor
vessel
rang
vp
qpcr
across
four
run
rabg
two
run
rvf
two
run
metrap
ie
human
dose
c
vp
consist
previou
report
tff
adenoviru
product
use
variou
devic
polyethersulfon
pe
membran
kda
molecular
weight
cutoff
mwco
obtain
satisfactori
result
use
kda
mwco
biomax
pe
cscreen
pellicon
pellicon
mini
devic
merck
pellicon
mini
devic
recoveri
typic
c
virus
concentr
diavolum
dv
buffer
exchang
anion
exchang
load
buffer
achiev
reduct
residu
hostcel
protein
reduc
hostcel
dna
undetect
level
diafiltr
beyond
dv
achiev
reduct
residu
next
sought
compar
rang
commerci
avail
anion
exchang
media
use
bind
wash
elut
mode
smallscal
experi
use
ml
media
focus
effort
upon
membran
monolith
matric
quaternari
amin
chemistri
compar
beadbas
resin
matric
provid
much
improv
convect
access
larg
speci
virus
bind
group
higher
bind
capac
speci
substanti
higher
flow
rate
matrix
volum
ratio
purpos
manufactur
small
gmp
batch
also
substanti
advantag
offtheshelf
avail
gmpsuitabl
dispos
capsul
size
suitabl
purif
vp
avoid
need
pack
customs
column
beadbas
resin
observ
satisfactori
result
three
matric
mustang
q
membran
capsul
natriflo
hdq
hydrogel
membran
capsul
cimqa
monolith
fig
satisfactori
separ
natriflo
hdq
capsul
requir
transfer
viru
phosphat
buffer
prior
applic
column
bind
capac
viru
recoveri
host
cell
protein
reduct
shown
fig
like
scaledup
process
could
design
use
media
work
select
mustang
q
capsul
basi
bind
capac
product
recoveri
host
cell
protein
reduct
ascertain
elut
condit
serotyp
perform
smallscal
gradient
elut
mustang
q
membran
metrap
elut
mscm
rvf
mscm
fig
l
draw
upon
experi
scaleddown
experi
implement
downstream
process
shown
fig
ensur
productcontact
compon
dispos
singleus
liner
merck
use
pellicon
mini
tff
cassett
chromatographi
monitor
employ
singleus
pressur
conduct
uv
spectrometri
sensor
flow
cell
pendotech
data
shown
fig
differ
process
differ
virus
choic
anion
exchang
wash
elut
conduct
shown
fig
base
upon
differ
elut
characterist
observ
smallscal
experi
fig
l
metrap
wash
perform
load
buffer
higherconduct
wash
omit
view
lower
elut
conduct
modest
amount
impur
elut
wash
step
serotyp
viru
obtain
human
dose
l
cultur
tabl
recoveri
process
step
shown
tabl
substanti
loss
note
iex
singl
run
use
pellicon
unit
product
qualiti
within
specif
accept
clinic
use
local
regul
particl
infect
p
ratio
ratio
residu
hostcel
protein
hostcel
dna
benzonas
result
assay
perform
inform
also
consist
high
qualiti
product
empti
capsid
vp
ratio
quantif
coomassiestain
sdspage
tabl
fig
p
ratio
simian
adenoviru
serotyp
commonli
higher
usual
obtain
even
purif
ultracentrifug
valu
rang
commonli
obtain
labscal
ultracentrifug
base
upon
experi
viru
prepar
jenner
institut
viral
vector
core
facil
batch
prepar
clinic
trial
clinic
biomanufactur
facil
p
ratio
rang
method
gmp
product
varieti
adenoviru
vector
varieti
scale
previous
report
focus
upon
develop
process
could
rapidli
adapt
adenoviru
serotypetransgen
combin
produc
small
gmp
batch
suitabl
earlyphas
clinic
trial
aim
simplic
transfer
view
increas
interest
product
adenoviru
vector
divers
context
includ
though
limit
use
low
middleincom
countri
respons
outbreak
emerg
pathogen
veterinari
use
result
process
suitabl
adopt
facil
compet
routin
bioprocess
procedur
mammalian
cell
cultur
bioreactor
batch
process
tangenti
flow
filtrat
chromatographi
key
element
use
cell
line
minim
need
virusantigen
specif
growth
optim
use
entir
offtheshelf
equip
materi
singleus
productcontact
materi
throughout
two
bioreactor
vessel
use
upstream
process
bioblu
vessel
eppendorf
advantag
noninvas
ph
sens
nonetheless
given
rel
low
cost
invas
ph
sensor
compat
mobiu
vessel
c
usd
could
regard
singleus
item
gmp
product
run
vessel
could
readili
use
cleanroom
exist
capabl
grow
mammalian
cell
suspens
shake
flask
scale
ga
requir
addit
co
underbench
medic
air
cylind
manufactur
offer
famili
larger
vessel
scaledup
product
somewhat
choic
lower
end
bioblu
rang
due
desir
simplic
satisfactori
result
process
deliber
pursu
intensif
upstream
process
modern
media
formul
fed
batch
perfus
process
clearli
varieti
option
avail
increas
volumetr
yield
upstream
process
similarli
priorit
simplic
consum
cost
rel
small
compon
total
cost
gmp
run
scale
therefor
satisfi
host
cell
dna
reduct
achiev
benzonas
uml
eas
quantifi
residu
benzonas
offtheshelf
elisa
kit
despit
rel
high
cost
compar
altern
method
precipit
domiphen
pharmaceuticalgrad
benzonas
concentr
cost
c
usd
per
liter
c
usd
per
vaccin
dose
trivial
context
manufactur
phase
clinic
trial
batch
inde
might
toler
market
product
certain
context
nonetheless
data
fig
suggest
scale
process
concentr
benzonas
use
digest
time
could
consider
reduc
maintain
accept
host
cell
dna
level
without
requir
chang
method
condit
use
reduc
host
cell
dna
beneath
regulatorilyaccept
level
ng
per
human
dose
prior
clarif
consider
higher
level
stage
would
expect
reduc
within
accept
limit
downstream
process
varieti
commerci
anion
exchang
product
shown
provid
accept
result
notabl
result
knowledg
first
publish
report
use
natriflo
hdq
hydrogel
membran
devic
viral
purif
avail
rang
size
suitabl
process
scale
scaleddown
process
develop
scaledup
product
observ
substanti
higher
dynam
bind
capac
previou
report
similar
mediasubstanti
excess
vp
per
ml
bed
three
media
primari
measur
bind
capac
made
use
prepurifi
viru
favour
high
capac
compar
use
load
includ
impur
nonetheless
routin
observ
total
process
yield
vp
use
ml
mustang
q
capsul
fullscal
process
capac
clear
benefici
implic
process
scalabl
costeffect
mustang
q
unit
avail
bed
volum
ml
data
suggest
would
adequ
purif
nearli
million
human
dose
observ
slightli
differ
elut
characterist
three
test
serotyp
although
salt
concentr
requir
elut
variou
adenoviru
serotyp
anion
exchang
media
previous
report
correl
charg
hexon
major
capsid
protein
observ
pattern
ph
predict
hexon
net
charg
data
also
collect
result
parallel
data
omit
graph
clarityin
panel
ai
column
graph
repres
data
singl
type
media
per
column
caption
panel
af
show
chromatogram
experi
previous
purifi
rabg
load
mustang
q
acrodisc
natriflo
hdq
recon
mini
cimqa
ml
capsul
panel
ac
breakthrough
observ
henc
dynam
bind
capac
calcul
mustang
q
natriflo
capsul
breakthrough
observ
load
vp
larger
cimqa
column
panel
df
show
continu
experi
viru
elut
use
linear
gradient
increas
conduct
allow
estim
elut
condit
conduct
peak
viru
elut
shown
panel
gi
show
chromatogram
experi
diafilt
lysat
contain
rabg
load
mustang
q
acrodisc
natriflo
hdq
recon
mini
cimqa
ml
capsul
follow
step
elutionpanel
j
present
dbc
viru
recoveri
hcp
reduct
data
experi
shown
panel
af
case
cimqa
column
breakthrough
reach
despit
load
vp
ml
devicepanel
kl
show
chromatogram
experi
previous
purifi
metrap
rvf
load
mustang
q
acrodisc
capsul
elut
linear
conduct
gradient
report
correl
elut
characterist
charg
found
relationship
compar
virus
hexon
charg
span
rang
relationship
imperfect
compar
virus
smaller
differ
may
chromatograph
differ
virus
share
similar
hexon
charg
attribut
differ
charg
structur
protein
serotyp
test
repres
divers
major
structur
protein
hexon
fiber
sequenc
within
adenoviru
speci
e
would
interest
extend
use
process
clinic
relev
serotyp
adenoviru
speci
encourag
work
sever
report
applic
tff
case
load
occur
first
ml
degre
deflect
impur
flowthrough
visibl
largest
peak
repres
elut
viru
collect
note
rabg
preelut
wash
postelut
highsalt
wash
produc
rel
small
peak
predominantli
impur
viru
assess
sdspage
data
obtain
use
uv
conduct
sensor
akta
purifi
data
obtain
use
complet
singleus
chromatographi
rig
ie
singleus
uv
conduct
sensor
pendotech
postelut
wash
perform
due
lower
conduct
vaccin
elut
preelut
wash
usedpanel
c
show
sampl
stage
downstream
process
coomassiestain
sdspage
gel
sampl
shown
singl
process
run
rabg
vaccin
typic
run
three
investig
vaccin
anionexchangebas
downstream
process
speci
b
adenoviru
speci
c
viru
anion
exchang
also
success
appli
speci
virus
given
residu
host
cell
protein
level
within
accept
limit
singlestep
chromatographi
requir
explor
polish
step
although
note
possibl
use
coreshel
octylamin
resin
captocor
ge
provid
polish
flowthrough
mode
downstream
process
thu
strikingli
straightforward
access
gmp
facil
minim
equip
invest
requir
peristalt
pump
pendotech
sensor
monitor
apparatu
total
oneoff
cost
usd
final
process
provid
usp
yield
consist
dose
per
litr
yield
per
infect
cell
rang
vp
favour
compar
valu
previous
report
review
encompass
varieti
cell
type
media
process
type
adher
suspens
batch
fed
batch
perfus
also
compar
also
achiev
recent
perfusionbas
process
use
cell
overal
dsp
recoveri
case
low
offer
clear
scope
improv
overal
process
yield
analysi
step
recoveri
individu
run
indic
particular
potenti
improv
rvf
iex
step
consist
perform
step
nonetheless
final
yield
consist
adequ
earlyphas
clinic
trial
method
implement
new
vaccin
minim
even
vaccinespecif
process
develop
given
one
two
week
possibl
perform
shake
flask
studi
confirm
optim
time
harvest
smallscal
gradientelut
anion
exchang
experi
confirm
suitabl
chromatographi
elut
wash
condit
among
vaccin
singl
adenoviru
serotyp
howev
transgen
repress
minim
differ
growth
kinet
chromatograph
characterist
believ
determin
constant
structur
protein
rather
vari
transgen
like
condit
preestablish
suitabl
given
serotyp
ie
condit
use
applic
regardless
transgeneand
henc
even
simpl
optim
experi
may
necessari
assur
satisfactori
yield
earlyphas
clinic
trial
key
ratelimit
step
product
gmp
adenoviru
outbreakrespons
context
rescu
viru
product
suitabl
inoculum
c
iu
initi
process
ongo
work
institut
aim
address
issu
work
support
merck
kgaa
uk
medic
research
council
grant
uk
engin
physic
scienc
research
council
grant
add
support
wellcom
trust
grant
jenner
investig
studi
perform
collabor
univers
oxford
merck
kgaa
partner
review
manuscript
prior
submiss
funder
input
design
studi
decis
publish
correspond
request
materi
address
sandydougla
ndmoxacuk
